| Literature DB >> 31210143 |
Thiago Silva Torres1, Kelika A Konda2, E Hamid Vega-Ramirez3,4, Oliver A Elorreaga2, Dulce Diaz-Sosa3,4, Brenda Hoagland1, Steven Diaz5, Cristina Pimenta6, Marcos Bennedeti1, Hugo Lopez-Gatell7, Rebeca Robles-Garcia4, Beatriz Grinsztejn1, Carlos Caceres2, Valdilea G Veloso1.
Abstract
BACKGROUND: HIV disproportionally affects key populations including men who have sex with men (MSM). HIV prevalence among MSM varies from 17% in Brazil and Mexico to 13% in Peru, whereas it is below 0.5% for the general population in each country. Pre-exposure prophylaxis (PrEP) with emtricitabine/tenofovir is being implemented in the context of combination HIV prevention. Reports on willingness to use PrEP among MSM have started to emerge over the last few years. Previously reported factors associated with willingness to use PrEP include awareness, higher sexual risk behavior, and previous sexually transmitted infection.Entities:
Keywords: Latin America; men who have sex with men; pre-exposure prophylaxis; prevention; surveys and questionnaires
Year: 2019 PMID: 31210143 PMCID: PMC6601256 DOI: 10.2196/13771
Source DB: PubMed Journal: JMIR Public Health Surveill ISSN: 2369-2960
Characteristics of the individuals who completed the questionnaire in Brazil, Mexico, and Peru (2018).
| Characteristics | Brazil | Mexico | Peru | Total | P valuea | ||
| 18-24 | 3222 (28.35) | 1766 (29.76) | 889 (41.23) | 5877 (30.21) | <.001 | ||
| 25-35 | 5364 (47.19) | 2991 (50.40) | 970 (44.99) | 9325 (47.93) | N/A | ||
| ≥36 | 2780 (24.46) | 1177 (19.83) | 297 (13.78) | 4254 (21.86) | N/A | ||
| Race (nonwhitec; n=13,446), n (%) | 5363 (47.18) | N/A | 1672 (80.42) | 7035 (52.32) | <.001 | ||
| Low | 5136 (45.18) | 1544 (28.79) | 710 (36.79) | 7390 (39.60) | — | ||
| Middle | 4700 (41.35) | 2400 (44.75) | 948 (49.12) | 7087 (37.98) | N/A | ||
| High | 1531 (13.47) | 1419 (26.46) | 272 (14.09) | 4183 (22.42) | N/A | ||
| Schooling (≤ secondary education; n=19,300), n (%) | 4378 (38.86) | 1395 (23.60) | 461 (21.69) | 6234 (32.30) | <.001 | ||
| Men | 10,386 (91.54) | 5212 (88.14) | 1708 (79.74) | 17,306 (89.20) | N/A | ||
| Women | 152 (1.34) | 54 (0.91) | 67 (3.13) | 273 (1.41) | N/A | ||
| Men/women | 808 (7.12) | 647 (10.94) | 367 (17.13) | 1822 (9.39) | N/A | ||
| Steady partner (yes; n=19,294), n (%) | 2916 (25.83) | 1576 (26.77) | 607 (28.67) | 5099 (26.43) | .02 | ||
| Grindr | 7623 (67.06) | 4801 (80.91) | 925 (42.90) | 13,349 (68.61) | N/A | ||
| Hornet | 2489 (21.90) | 569 (9.59) | 20 (0.93) | 3078 (15.82) | N/A | ||
| 780 (6.86) | 230 (3.88) | 1037 (48.10) | 2047 (10.52) | N/A | |||
| Other | 475 (4.18) | 334 (5.63) | 174 (8.07) | 983 (5.05) | N/A | ||
| Never | 835 (7.35) | 432 (7.28) | 414 (19.20) | 1681 (8.64) | N/A | ||
| Sometimes | 4387 (38.60) | 3336 (56.22) | 1033 (47.91) | 8756 (45.01) | N/A | ||
| Daily | 6142 (54.05) | 2166 (36.50) | 709 (32.88) | 9017 (46.35) | N/A | ||
| Previous 3 months | 3516 (31.12) | 1428 (21.15) | 551 (25.74) | 5495 (28.39) | N/A | ||
| Previous 6 months | 1989 (17.60) | 1031 (17.44) | 321 (14.99) | 3341 (17.26) | N/A | ||
| Previous 12 months | 1835 (16.24) | 843 (14.26) | 277 (12.94) | 2955 (15.27) | N/A | ||
| More than 12 months | 1972 (17.45) | 1259 (21.29) | 468 (21.86) | 3699 (19.11) | N/A | ||
| Never | 1986 (17.58) | 1352 (22.86) | 524 (24.47) | 3862 (19.96) | N/A | ||
| Low | 7746 (70.22) | 3341 (57.41) | 1218 (57.78) | 12,305 (64.90) | N/A | ||
| Middle | 2299 (20.84) | 1845 (31.70) | 652 (30.93) | 4796 (25.30) | N/A | ||
| High | 986 (8.94) | 634 (10.89) | 238 (11.29) | 1858 (9.80) | N/A | ||
| Preliminary eligibility for PrEPf (n=19,419), n (%) | 7938 (70.03) | 3668 (61.85) | 1504 (69.82) | 13,110 (67.51) | <.001 | ||
| None | 873 (7.68) | 1401 (23.82) | 345 (16.2) | 2619 (13.52) | N/A | ||
| 1-5 | 6036 (53.11) | 2872 (48.84) | 1145 (53.78) | 10,053 (51.88) | N/A | ||
| 6-10 | 1958 (17.23) | 821 (13.96) | 290 (13.62) | 3069 (15.84) | N/A | ||
| >10 | 2499 (21.99) | 787 (13.38) | 349 (16.39) | 3635 (18.76) | N/A | ||
| Condomless receptive anal sexg (yes; n=19,326), n (%) | 4433 (39.34) | 2368 (40.04) | 954 (44.48) | 7755 (40.13) | <.001 | ||
| Condomless insertive anal sexg (yes; n=19,322), n (%) | 5106 (45.31) | 2511 (42.45) | 960 (44.90) | 8577 (44.39) | <.001 | ||
| Sex with HIV+ male partnerg (yes; n=19,270), n (%) | 1217 (10.82) | 712 (12.08) | 269 (12.64) | 2198 (11.41) | .002 | ||
| Sex with unknown HIV status male partnerg (yes; n=19,133), n (%) | 3911 (35.27) | 2956 (49.98) | 1108 (52.02) | 7975 (41.68) | <.001 | ||
| Sex under alcohol useg (yes; n=19,414), n (%) | 4190 (36.97) | 2089 (35.23) | 778 (36.15) | 7057 (36.35) | .08 | ||
| Chemsexg (yes; n=19,401), n (%) | 1993 (17.60) | 948 (16.00) | 243 (11.29) | 3184 (16.41) | <.001 | ||
| Transactional sexg (yes; n=19,456), n (%) | 616 (5.42) | 271 (4.57) | 155 (7.19) | 1042 (5.36) | <.001 | ||
| STI diagnosesfg,h (yes; n=18,875), n (%) | 1476 (13.25) | 372 (6.52) | 197 (9.70) | 2045 (10.83) | <.001 | ||
| PEPi awareness (yes; n=19,457), n (%) | 7510 (66.07) | 3269 (55.09) | 778 (36.09) | 11,557 (59.40) | <.001 | ||
| PEP use (yes; n=19,393), n (%) | 1452 (12.82) | 310 (5.24) | 81 (3.76) | 1843 (9.50) | <.001 | ||
| Binge drinkingg (yes; n=19,390), n (%) | 7774 (68.39) | 4094 (69.43) | 1518 (71.40) | 13,386 (69.04) | <.001 | ||
| Tobacco | 2905 (25.56) | 1981 (35.87) | 539 (26.72) | 5425 (28.69) | <.001 | ||
| Marijuana or hash | 2907 (25.57) | 1369 (24.79) | 471 (23.35) | 4747 (25.11) | .09 | ||
| Stimulantsj | 1622 (14.27) | 545 (9.87) | 130 (6.45) | 2297 (12.15) | <.001 | ||
| Hallucinogensk | 994 (8.74) | 248 (4.49) | 28 (1.39) | 1270 (6.72) | <.001 | ||
| Poppers | 735 (6.47) | 1233 (22.33) | 195 (9.67) | 2163 (11.44) | <.001 | ||
| Erectile dysfunction drugg | 1054 (9.27) | 605 (10.96) | 90 (4.46) | 1749 (9.25) | <.001 | ||
aChi-square test.
bN/A: not applicable.
cBlack, Asian, Native American, and Mix race; this question was not available for Mexican respondents.
dFor Brazil, we considered the number of minimum wages in the family monthly income: low ≤3, middle 4-10, high >10 (monthly minimum wage in 2018 was 954 BRL=US $250, currency from June 2018). For Peru, we considered individual monthly income, categorized by number of minimum salaries: low ≤3, middle 4-10, high >10 (monthly minimum wage in 2018 was 850 PEN=US $265). For Mexico, we considered individual monthly income, categorized by number of minimum salaries: low: from no income to <3, middle 3-4, high ≥ 5 (monthly minimum wage in 2018 was 2686 MXN=US $141).
eIn the next year.
fAdapted from the WHO criteria for pre-exposure prophylaxis, which included the following: unprotected anal sex with a male or trans partner, sex with an HIV-positive partner, sex work, or STI diagnosis; all in the past 6 months.
gDuring the previous 6 months.
hSyphilis, gonorrhea, or rectal chlamydia.
iPEP: postexposure prophylaxis.
jCocaine, crack, ecstasy, and GHB (4-hydroxybutanoic acid).
kSolvents, lysergic acid diethylamide, and ketamine.
Figure 1Study flowchart. Brazil, Mexico and Peru, 2018.
Awareness, willingness to use, barriers, and facilitators to daily oral pre-exposure prophylaxis in Brazil, Mexico, and Peru (2018).
| Variables | Brazil | Mexico | Peru | Total | |||
| PrEPb awareness (yes; n=19,396c) | 7794 (68.82) | 3796 (64.11) | 1002 (46.60) | 12,592 (64.92) | <.001 | ||
| Willingness to use PrEP (yes) | 7099 (62.45) | 4158 (70.07) | 1241 (57.56) | 12,498 (64.23) | <.001 | ||
| Never | 10,875 (95.67) | 5735 (96.97) | 2075 (96.78) | 18,685 (96.19) | N/Ad | ||
| Current | 266 (2.34) | 87 (1.47) | 42 (1.96) | 395 (2.03) | N/A | ||
| Past | 226 (1.99) | 92 (1.56) | 27 (1.26) | 345 (1.78) | N/A | ||
| Anticipated risk compensation (yes) | 2325 (20.45) | 1380 (23.26) | 543 (25.19) | 4248 (21.83) | <.001 | ||
| PrEP if part of Ministry of Health program (yes) | 5814 (51.15) | 4113 (69.31) | 1165 (54.04) | 11,092 (57.01) | <.001 | ||
| Daily oral | 3802 (33.45) | 2260 (37.92) | 719 (33.35) | 6771 (34.80) | N/A | ||
| Event-driven | 2494 (21.94) | 1491 (25.13) | 553 (25.65) | 4538 (23.32) | N/A | ||
| Injectable | 5071 (44.61) | 2193 (36.96) | 884 (41.00) | 8148 (41.88) | N/A | ||
| Afraid of short-term side effects | 6805 (59.87) | 4126 (69.53) | 1614 (74.86) | 12,545 (64.48) | <.001 | ||
| Afraid of long-term side effects | 7601 (66.87) | 4601 (77.54) | 1721 (79.82) | 13,923 (71.56) | <.001 | ||
| Afraid that antiretroviral therapy would not work if infected | 6522 (57.38) | 5031 (84.78) | 1810 (83.95) | 13,363 (68.68) | <.001 | ||
| Afraid of not being 100% protected against HIV | 7831 (68.89) | 4900 (82.57) | 1794 (83.21) | 14,525 (74.65) | <.001 | ||
| Taking pills everyday | 5774 (50.80) | 2497 (42.08) | 1049 (48.65) | 9320 (47.90) | <.001 | ||
| Talking to a doctor about sex life | 2670 (23.49) | 1897 (31.97) | 886 (41.09) | 5453 (28.03) | <.001 | ||
| Having HIV/ sexually transmitted infection testing every 3 months | 5025 (44.21) | 2615 (44.07) | 1120 (51.95) | 8760 (45.02) | <.001 | ||
| Taking PrEP means that I am at risk of HIV infection | 4540 (39.94) | 3339 (56.27) | 1203 (55.80) | 9082 (46.68) | <.001 | ||
| My partners may expect condomless anal sex | 4310 (37.92) | 3584 (60.40) | 1190 (55.19) | 9084 (46.69) | <.001 | ||
| Afraid that people may think I am HIV+ | 4303 (37.86) | 1966 (33.13) | 950 (44.06) | 7219 (37.10) | <.001 | ||
| Afraid that people ask me why I am using PrEP when they see me taking the pills | 3709 (32.63) | 1663 (28.02) | 880 (40.82) | 6252 (32.13) | <.001 | ||
| Free PrEP | 8797 (77.39) | 4317 (72.75) | 1474 (68.37) | 14,588 (74.98) | <.001 | ||
| Access to free HIV test | 8573 (75.42) | 4554 (76.74) | 1567 (72.68) | 14,694 (75.52) | .001 | ||
| Access to other free exams | 8052 (70.84) | 4285 (72.21) | 1499 (69.53) | 13,836 (71.11) | .04 | ||
| Access to personal PrEP counseling | 7103 (62.49) | 4129 (69.58) | 1444 (66.98) | 12,676 (65.15) | <.001 | ||
| Support from apps or messages | 5464 (48.07) | 2880 (48.53) | 1160 (53.80) | 9504 (48.85) | <.001 | ||
| Support and counseling about my sex life | 4272 (37.58) | 3138 (52.88) | 1175 (54.50) | 8585 (44.12) | <.001 | ||
aChi-square test.
bPrEP: pre-exposure prophylaxis.
cThe full sample, N=19,457, is included unless otherwise specified.
dN/A: not applicable.
eBarriers were grouped into PrEP information, beliefs, and behaviors. The percent shown is of participants responding that the barrier was important or very important.
fThe percent shown is of participants responding that the facilitator was very important.
Figure 2Willingness to use daily oral pre-exposure prophylaxis per region. Brazil, Mexico and Peru, 2018. Percentage of willingness to use daily oral prep is given per region; n is total number of participants per region or country.
Factors associated with willingness to use daily oral pre-exposure prophylaxis in Brazil, Mexico, and Peru (2018).
| Variable Variable | Brazil | Mexico | Peru | ||||
| Bivariate models, ORa (95% CI) | Multivariate model, AORb (95% CI)c | Bivariate models, OR (95% CI) | Multivariate model, AOR (95% CI)c | Bivariate models, OR (95% CI) | Multivariate model, AOR (95% CI)c | ||
| 18-24 | Ref.d | Ref. | Ref. | Ref. | Ref. | Ref. | |
| 25-35 | 0.95 (0.86-1.06) | 1.06 (0.93-1.21) | 1.06 (0.85-1.34) | ||||
| ≥36 | 0.97 (0.86-1.10) | 0.95 (0.81-1.11) | 1.36 (0.97-1.90) | ||||
| Color (nonwhitee vs white) | 0.95 (0.88-1.02) | 1.01 (0.93-1.10) | N/Af | N/A | 0.88 (0.70-1.09) | —g | |
| Low | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | |
| Middle | 1.08 (0.99-1.19) | 1.05 (0.90-1.23) | 0.99 (0.84-1.18) | ||||
| High | 1.11 (0.96-1.28) | 0.92 (0.78-1.11) | 1.20 (0.84-1.71) | ||||
| Schooling (any postsecondary education vs ≤ secondary education) | 0.99 (0.90-1.08) | 1.07 (0.92-1.26) | 1.19 (0.96-1.46) | 0.86 (0.66-1.12) | |||
| Steady partner (yes vs no) | 1.06 (0.97-1.16) | — | — | 1.05 (0.87-1.27) | — | ||
| HIV testing (at least once lifetime vs never) | — | — | |||||
| Never | Ref. | — | Ref. | Ref. | Ref. | Ref. | |
| Sometimes | 1.06 (0.91-1.23) | — | 1.15 (0.90-1.47) | 1.18 (0.91-1.53) | |||
| Daily | — | ||||||
| Low | Ref. | Ref. | Ref. | — | Ref. | Ref. | |
| Middle | — | ||||||
| High | — | ||||||
| Preliminary eligibility for PrEPj (yes vs no) | — | ||||||
| Number of male sexual partnersk (>5 vs ≤5) | — | ||||||
| Sex under alcohol usek (yes vs no) | — | — | 1.08 (0.89-1.30) | — | |||
| Chemsexk (yes vs no) | — | — | — | ||||
| PrEP awareness (yes vs no) | |||||||
| Anticipated risk compensation (yes vs no) | — | ||||||
| Barriers: Information, mean (SD) | — | ||||||
| Barriers: Behaviors, mean (SD) | |||||||
| Barriers: Believes, mean (SD) | |||||||
| Facilitators, mean (SD) | |||||||
aOR: odds ratio.
bAOR: adjusted odds ratio.
cVariables with P<.01 in bivariate models were included in the initial multivariable model. Variables with P<.05 were kept in the final multivariable models, excepted for age, monthly income, and schooling defined a priori for all countries, and race only for Brazil; statistically significant associations at P<.05 in italics. Region did not remain in the final multivariate models and bivariate analysis is not shown.
dRef.: reference.
eBlack, Asian, Native American, or Mix race.
fN/A: not applicable.
gNot statistically significant.
hFor Brazil, we considered the number of minimum wages in the family monthly income: low ≤3, middle 4-10, high >10 (monthly minimum wage in 2018 was 954 BRL=US $250, currency from June 2018). For Peru, we considered individual monthly income, categorized by number of minimum salaries: low ≤3, middle 4-10, high >10 (monthly minimum wage in 2018 was 850 PEN=US $265). For Mexico, we considered individual monthly income, categorized by number of minimum salaries: low, from no income to <3, middle 3-4, high ≥ 5 (monthly minimum wage in 2018 was 2686 MXN=US $141).
iIn the next 12 months.
jAdapted from the WHO criteria for pre-exposure prophylaxis, which included the following: unprotected anal sex with a male or trans partner, sex with an HIV-positive partner, sex work, or STI diagnosis; all in the past 6 months.
kDuring the previous 6 months.